David L. Rimm, MD, PhD

Explore the evolving role of Trop-2 in non-small cell lung cancer and the importance of larger studies and biomarkers for future treatments.

Recent studies on Trop2-ADC reveal promising predictive biomarkers for lung cancer treatment, sparking excitement while urging caution for further research.

Discover the groundbreaking QCS method for measuring Trop-2 in lung cancer, enhancing accuracy and objectivity in biomarker assessment.

Exploring the complexities of Trop-2 expression in cancer, this discussion highlights challenges in measurement and its implications for treatment efficacy.

Explore the evolving role of Trop-2 in non-small cell lung cancer, including measurement techniques and emerging therapeutic insights.

David Rimm, MD, PhD, discusses how FDA-approved IHC assays may lack reproducibility in real-world settings in breast cancer.

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses the continued role for PD-L1 testing to predict response with checkpoint inhibitors in non­–small cell lung cancer (NSCLC).

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses various options for biomarker testing in lung cancer.